Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VKORC1 | Q9BQB6 | 4/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.65 |
| ▸ | ALB | P02768 | 2/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | PCSK7 | Q16549 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | NQO1 | P15559 | 1/20 | 0.60 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.55 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14034056 | 0.88 | NQO1 (0.67) | VKORC1CYP2C9ALBHSD17B10KDM4E | |
| SCHEMBL14033502 | 0.87 | VKORC1 (0.63) | VKORC1CYP2C9ALBHSD17B10KDM4E | |
| SCHEMBL14033878 | 0.81 | VKORC1 (0.71) | VKORC1CYP2C9ALBHSD17B10KDM4E | |
| SCHEMBL1649113 | 0.80 | NQO1 (0.76) | VKORC1CYP2C9ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL29400364 | 0.79 | CYP2C9 (1.00) | VKORC1CYP2C9ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL3792087 | 0.79 | CYP2C9 (1.00) | VKORC1CYP2C9ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL2139452 | 0.79 | CYP2C9 (1.00) | VKORC1CYP2C9ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL4439794 | 0.79 | CYP2C9 (1.00) | VKORC1CYP2C9ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL662875 | 0.79 | CYP2C9 (1.00) | VKORC1CYP2C9ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL36362 | 0.78 | CYP2C9 (0.97) | VKORC1CYP2C9ALBHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439077-B2 | Coumarin analog compounds for safer anticoagulant treatment | NEW CENTURY PHARMACEUTICALS, INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-20070155828-A1 | Coumarin analog compounds for safer anticoagulant treatment | CARTER DANIEL C | 2007-07-05 | — | — | US | disclosed |
| US-7179838-B2 | Coumarin analog compounds for safer anticoagulant treatment | NEW CENTURY PHARMACEUTICALS, INC. (US) | 2007-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155828-A1 | Coumarin analog compounds for safer anticoagulant treatment | SERPINC1, PROC, ALB | VKORC1 11/4885CYP2C9 37/4885ALB 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.